Image: Novartis AG
Novartis has urged the US Food and Drug Administration (FDA) to allow biosimilars to bear the same international nonproprietary names (INNs) as their reference products.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, Sandoz, FDA, biosimilars, INNs